Taiwan Bio Therapeutics , Ltd Profit Margin

The latest profit margin for 6892.TWO is -396.79% as of June 2025. That compares with -226.62% in the prior-year period — down 75.1% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Taiwan Bio Therapeutics , Ltd's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6892.TWO's profit margin moved from -226.62% to -396.79% — a 75.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Taiwan Bio Therapeutics , Ltd's valuation or profitability profile.

Against Healthcare companies, 6892.TWO currently prints -396.79% for profit margin, while the sector average sits near 10.58%. That is roughly 3850.2% below the sector mean. Large gaps often invite a closer look at Taiwan Bio Therapeutics , Ltd's growth, margins, and balance sheet.

Profit Margin shows how effectively Taiwan Bio Therapeutics , Ltd converts resources into returns. At -396.79%, 6892.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -226.62% in the prior-year period — down 75.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 6892.TWO's profit margin (-396.79%), review year-over-year change from -226.62%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.